Int. J. Mol. Sci. 2013, 14(6), 11347-11355; doi:10.3390/ijms140611347
Article

Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI

1 Department of Urology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands 2 Department of Radiology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
* Author to whom correspondence should be addressed.
Received: 1 April 2013; in revised form: 21 May 2013 / Accepted: 23 May 2013 / Published: 28 May 2013
(This article belongs to the Special Issue Molecular Research in Urology)
PDF Full-text Download PDF Full-Text [309 KB, uploaded 28 May 2013 15:09 CEST]
Abstract: PCA3 (prostate cancer gene 3) and multiparametric 3 tesla MRI are new promising diagnostic tools in the detection of PCa. Our aim was to study the clinical value of the Progensa PCA3-test: its predictive value for biopsy outcome, Gleason score and MRI outcome. We evaluated, retrospectively, 591 patients who underwent a Progensa PCA3-test at the Radboud University Nijmegen Medical Centre between May 2006 and December 2009. Prostate biopsies were performed in 290 patients; a multiparametric 3 tesla MRI of the prostate was performed in 163/591 patients. The PCA3-score was correlated to biopsy results and MRI outcome. The results show that PCA3 was highly predictive for biopsy outcome (p < 0.001); there was no correlation with the Gleason score upon biopsy (p = 0.194). The PCA3-score of patients with a suspicious region for PCa on MRI was significantly higher (p < 0.001) than in patients with no suspicious region on MRI (52 vs. 21). In conclusion, PCA3 is a valuable diagnostic biomarker for PCa; it did not correlate with the Gleason score. Furthermore, multiparametric MRI outcome was significantly correlated with the PCA3-score. Thus, PCA3 could be used to select patients that require MRI. However, in patients with a negative PCA3 and high clinical suspicion of PCa, a multiparametric MRI should also be done.
Keywords: prostate cancer; PCA3; MRI

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Leyten, G.H.J.M.; Wierenga, E.A.; Sedelaar, J.P.M.; van Oort, I.M.; Futterer, J.J.; Barentsz, J.O.; Schalken, J.A.; Mulders, P.F.A. Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI. Int. J. Mol. Sci. 2013, 14, 11347-11355.

AMA Style

Leyten GHJM, Wierenga EA, Sedelaar JPM, van Oort IM, Futterer JJ, Barentsz JO, Schalken JA, Mulders PFA. Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI. International Journal of Molecular Sciences. 2013; 14(6):11347-11355.

Chicago/Turabian Style

Leyten, Gisele H.J.M.; Wierenga, Elisabeth A.; Sedelaar, J. P.M.; van Oort, Inge M.; Futterer, Jurgen J.; Barentsz, Jelle O.; Schalken, Jack A.; Mulders, Peter F.A. 2013. "Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI." Int. J. Mol. Sci. 14, no. 6: 11347-11355.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert